June 2, 2017 - NovaDigm Therapeutics Awarded $6 Million by U.S. Department of Defense to Conduct a Phase 2a Staphylococcus aureus Vaccine Trial
 Click here for complete story
August 15, 2016 - NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women With Recurrent Vulvovaginal Candidiasis (RVVC)
Click here for complete story
November 3, 2015 - NovaDigm Therapeutics’ Chief Executive Officer, Timothy Cooke, Appointed to the National Vaccine Advisory Committee
Click here for complete story
June 10, 2014 - NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio with Three New Antigens via Series of Rights Acquisitions
Click here for complete story
October 3, 2013 - NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine Against Candida
Click here for complete story
September 26, 2013 - NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis (RVVC)
Click here for complete story
December 13, 2012 - Results from Positive Phase 1 Study of NovaDigm Therapeutics’ NDV-3 Vaccine for Candida and Staph Infections Published in Vaccine
Click here for complete story
May 7, 2012 - NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine
Click here for complete story
Sep 26, 2011 - "NovaDigm Unveils Data with Dual Fungal/Bacterial Vaccine" – BioWorld Today Article
Click here for complete story
Sep 19, 2011 - NovaDigm Therapeutics Presents Positive Phase 1 Safety and Immunogenicity Data for NDV-3 Vaccine
Click here for complete story
Sep 19, 2011 - NovaDigm Therapeutics Presents Positive Preclinical Data in Vulvovaginal Candidiasis for NDV-3 Vaccine
Click here for complete story
Dec 3, 2009 - R. Gordon Douglas, Jr., appointed Chairman of the Board.
Click here for complete story
|
